Tivozanib
Tivozanib is a pharmaceutical drug with 27 clinical trials. Currently 4 active trials ongoing. Historical success rate of 68.4%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
12
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
59.1%
13 of 22 finished
40.9%
9 ended early
4
trials recruiting
27
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Tivozanib + Enzalutamide in Adv Prostate Cancer
Clinical Trials (27)
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Tivozanib + Enzalutamide in Adv Prostate Cancer
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Tivozanib for Recurrent Glioblastoma
Tivozanib As Maintenance Therapy In GYN
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 27